- Home
- ACB vs LAB Comparison
ACB vs LAB Comparison
Compare ACB & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACB
- LAB
- Stock Information
- Founded
- ACB 2013
- LAB 1999
- Country
- ACB Canada
- LAB United States
- Employees
- ACB N/A
- LAB N/A
- Industry
- ACB Pharmaceuticals and Biotechnology
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- ACB Health Care
- LAB Industrials
- Exchange
- ACB Nasdaq
- LAB Nasdaq
- Market Cap
- ACB 313.9M
- LAB 372.1M
- IPO Year
- ACB N/A
- LAB 2011
- Fundamental
- Price
- ACB $4.31
- LAB $1.29
- Analyst Decision
- ACB Hold
- LAB Buy
- Analyst Count
- ACB 1
- LAB 2
- Target Price
- ACB N/A
- LAB $2.50
- AVG Volume (30 Days)
- ACB 1.6M
- LAB 2.5M
- Earning Date
- ACB 06-18-2025
- LAB 07-30-2025
- Dividend Yield
- ACB N/A
- LAB N/A
- EPS Growth
- ACB N/A
- LAB N/A
- EPS
- ACB 0.03
- LAB N/A
- Revenue
- ACB $238,837,444.00
- LAB $169,687,000.00
- Revenue This Year
- ACB $12.22
- LAB N/A
- Revenue Next Year
- ACB $7.36
- LAB $12.18
- P/E Ratio
- ACB $149.95
- LAB N/A
- Revenue Growth
- ACB 27.32
- LAB 33.86
- 52 Week Low
- ACB $3.42
- LAB $0.92
- 52 Week High
- ACB $7.20
- LAB $2.41
- Technical
- Relative Strength Index (RSI)
- ACB 38.17
- LAB 55.09
- Support Level
- ACB $3.91
- LAB $1.17
- Resistance Level
- ACB $6.21
- LAB $1.31
- Average True Range (ATR)
- ACB 0.28
- LAB 0.10
- MACD
- ACB -0.14
- LAB 0.01
- Stochastic Oscillator
- ACB 15.31
- LAB 28.95
About ACB Aurora Cannabis Inc.
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.